Ozempic Tablet Relaunch Aims to Reclaim Market Share

Novo Nordisk has rebranded an existing diabetes tablet as Ozempic in the United States, a strategic maneuver designed to capitalize on the immense brand recognition of its globally popular Ozempic drug. This relaunch is set to begin on Monday, with the medication becoming available in specific doses for adult patients.

The Danish pharmaceutical company will introduce Ozempic pills in 1.5 mg, 4 mg, and 9 mg strengths. These new formulations are deemed as safe and effective as the previously marketed Rybelsus tablets, which contain the same active ingredient, semaglutide, but in different dosages and formulations.

This initiative represents a significant effort by Novo Nordisk to recapture market share from its main competitor, Eli Lilly. The company is banking on the success of new formulations of its best-selling medications and a more direct-to-consumer marketing strategy to achieve this goal.